Novartis Sues Apotex To Block Generic Exelon
Novartis filed its complaint Tuesday in the U.S. District Court for the District of Delaware, following Apotex's filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval for a copycat version of the dementia drug.
The complaint asserts that Apotex's ANDA infringes two patents, U.S. Patent Numbers 4,948,807 and 5,602,176. The...
To view the full article, register now.